FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255196403> ?p ?o ?g. }

• W4255196403 endingPage "2274" @default.
• W4255196403 startingPage "2274" @default.
• W4255196403 abstract "Abstract Background: Muscle invasive bladder cancer (MIBC) is a lethal disease with high recurrence rate despite standard radical cystectomy with neoadjuvant chemotherapy. Informative new biomarker strategies are needed to accurately assess the risk of recurrence and guide treatment. Epigenetic marks play a key regulatory role in cancer initiation and progression, and methylation patterns in the tissue have been correlated with prognosis in multiple cancer types. We hypothesized that whole-genome bisulfite sequencing (WGBS) can be used to generate a cell-free DNA (cfDNA) based methylation signature prognostic of bladder cancer recurrence after curative cystectomy. Methods: We identified a retrospective MIBC cohort with annotated clinical outcome more than 10 years after curative cystectomy. In the cohort, we selected a total of 46 patients who did not recur after 3 years of follow-up, and 40 patients who relapsed within 3 years of surgery. cfDNA was extracted from the archival plasma, and samples were pooled for WGBS based on their pathologic stages (T2a, T2b, T3a, T3b, and T4/N+) and recurrence status (recurrence vs no recurrence). A paired-end 150bp sequencing was performed on an Illumina NovaSeq platform. Sequences were aligned using the bismark tool and DNA methylation differences between groups were identified using metline. Results: CfDNA was extracted with a median cfDNA concentration 10.6 ng/ml (range 0.97-121.5 ng/ml). After WGBS, differential methylation regions (DMRs) for each stage were called by comparing the recurrence (R) and non-recurrence (NR) groups. We identified 6412 to 9532 DMRs across stages, and greater overall hypomethylation in cfDNA before systectomy in R groups was observed in all stages. While most of the DMRs are in the gene bodies, 10.3 to 11.7% of the DMRs were in the promoter regions. DMRs were also compared with publically available datasets using Basespace correlation engine. The cfDNA methylation in R groups across all stages was positively correlated with tumor tissue methylation in a bladder cancer dataset. Similarly, the cfDNA methylation in R groups was inversely correlated with bladder cancer tissue expression in TCGA dataset. We also called the DMRs by comparing all R and NR groups, and 729 DMRs were found to be shared in all stages. Similar patterns of global hypomethylation and positive correlation to the bladder cancer tissue methylation were observed in R group. Conclusions: cfDNA methylation in MIBC patients was concordant with multiple reported datasets. The overall hypomethylation in the cfDNA prior to the cystectomy was observed in patients who later recurred. Additional data filtering and annotation is ongoing, and these DMRs will be validated as potential biomarkers for predicting the risk of recurrence in MIBC patients. Citation Format: YI-TSUNG LU, Gerald Gooden, Ben Y. Tew, David Buckley, Kimberly Siegmund, Siamak Daneshmand, Amir Goldkorn, Bodour Salhia. Whole-genome bisulfite sequencing of cell-free DNA (cfDNA) in muscle-invasive bladder cancer patients to predict the risk of recurrence [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2274." @default.
• W4255196403 created "2022-05-12" @default.
• W4255196403 creator A5020601518 @default.
• W4255196403 creator A5023411724 @default.
• W4255196403 creator A5047940829 @default.
• W4255196403 creator A5049622431 @default.
• W4255196403 creator A5050155323 @default.
• W4255196403 creator A5053585879 @default.
• W4255196403 creator A5076385474 @default.
• W4255196403 creator A5079940072 @default.
• W4255196403 date "2019-07-01" @default.
• W4255196403 modified "2023-10-10" @default.
• W4255196403 title "Abstract 2274: Whole-genome bisulfite sequencing of cell-free DNA (cfDNA) in muscle-invasive bladder cancer patients to predict the risk of recurrence" @default.
• W4255196403 doi "https://doi.org/10.1158/1538-7445.am2019-2274" @default.
• W4255196403 hasPublicationYear "2019" @default.
• W4255196403 type Work @default.
• W4255196403 citedByCount "0" @default.
• W4255196403 crossrefType "journal-article" @default.
• W4255196403 hasAuthorship W4255196403A5020601518 @default.
• W4255196403 hasAuthorship W4255196403A5023411724 @default.
• W4255196403 hasAuthorship W4255196403A5047940829 @default.
• W4255196403 hasAuthorship W4255196403A5049622431 @default.
• W4255196403 hasAuthorship W4255196403A5050155323 @default.
• W4255196403 hasAuthorship W4255196403A5053585879 @default.
• W4255196403 hasAuthorship W4255196403A5076385474 @default.
• W4255196403 hasAuthorship W4255196403A5079940072 @default.
• W4255196403 hasConcept C104317684 @default.
• W4255196403 hasConcept C121608353 @default.
• W4255196403 hasConcept C126322002 @default.
• W4255196403 hasConcept C143998085 @default.
• W4255196403 hasConcept C150194340 @default.
• W4255196403 hasConcept C189235521 @default.
• W4255196403 hasConcept C190727270 @default.
• W4255196403 hasConcept C2775910329 @default.
• W4255196403 hasConcept C2780352672 @default.
• W4255196403 hasConcept C2781197716 @default.
• W4255196403 hasConcept C33288867 @default.
• W4255196403 hasConcept C41091548 @default.
• W4255196403 hasConcept C54355233 @default.
• W4255196403 hasConcept C71924100 @default.
• W4255196403 hasConcept C72563966 @default.
• W4255196403 hasConcept C86803240 @default.
• W4255196403 hasConceptScore W4255196403C104317684 @default.
• W4255196403 hasConceptScore W4255196403C121608353 @default.
• W4255196403 hasConceptScore W4255196403C126322002 @default.
• W4255196403 hasConceptScore W4255196403C143998085 @default.
• W4255196403 hasConceptScore W4255196403C150194340 @default.
• W4255196403 hasConceptScore W4255196403C189235521 @default.
• W4255196403 hasConceptScore W4255196403C190727270 @default.
• W4255196403 hasConceptScore W4255196403C2775910329 @default.
• W4255196403 hasConceptScore W4255196403C2780352672 @default.
• W4255196403 hasConceptScore W4255196403C2781197716 @default.
• W4255196403 hasConceptScore W4255196403C33288867 @default.
• W4255196403 hasConceptScore W4255196403C41091548 @default.
• W4255196403 hasConceptScore W4255196403C54355233 @default.
• W4255196403 hasConceptScore W4255196403C71924100 @default.
• W4255196403 hasConceptScore W4255196403C72563966 @default.
• W4255196403 hasConceptScore W4255196403C86803240 @default.
• W4255196403 hasIssue "13_Supplement" @default.
• W4255196403 hasLocation W42551964031 @default.
• W4255196403 hasOpenAccess W4255196403 @default.
• W4255196403 hasPrimaryLocation W42551964031 @default.
• W4255196403 hasRelatedWork W1698395555 @default.
• W4255196403 hasRelatedWork W1765225320 @default.
• W4255196403 hasRelatedWork W193408644 @default.
• W4255196403 hasRelatedWork W2034140656 @default.
• W4255196403 hasRelatedWork W2057329510 @default.
• W4255196403 hasRelatedWork W2570149195 @default.
• W4255196403 hasRelatedWork W2783061879 @default.
• W4255196403 hasRelatedWork W3004424038 @default.
• W4255196403 hasRelatedWork W3028104188 @default.
• W4255196403 hasRelatedWork W3110004869 @default.
• W4255196403 hasVolume "79" @default.
• W4255196403 isParatext "false" @default.
• W4255196403 isRetracted "false" @default.
• W4255196403 workType "article" @default.